Last reviewed · How we verify
QRL-101
At a glance
| Generic name | QRL-101 |
|---|---|
| Sponsor | QurAlis Corporation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Multiple Ascending Dose Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants (PHASE1)
- A Study Exploring the PK/PD Relationship of QRL-101 in Adults With ALS (PHASE1)
- A Study Evaluating the Pharmacokinetics of Three QRL-101 Formulations in Healthy Participants (PHASE1)
- A 3-way Cross-over Study on the Effects of QRL-101 on Transcranial Magnetic Stimulation and Nerve Excitability in Healthy Participants (PHASE1)
- A Study Evaluating Multiple Ascending Doses of QRL-101 in Healthy Participants (PHASE1)
- A Study Evaluating Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QRL-101 CI brief — competitive landscape report
- QRL-101 updates RSS · CI watch RSS
- QurAlis Corporation portfolio CI